Table 1.
General characteristics of the included studies.
| Reference (year) | TYPE | Country | Study period* | gender ratio (fem:male) | Mean age in years(range) | Number of patients ° |
|---|---|---|---|---|---|---|
| Alzouebi et al. (2012) (12) | TL | UK | 1970-2010 | 4.4:1 | 66 (20-90) | 70 |
| Buxey et al. (2012) (55) | TL | Australia | 1996-2009 | N/A | 72 (50-90) | 7 |
| Ha et al., 2016) (40) | TL and ATC | Korea | 2000-2012 | PTL 2.3:1 ATC 4.9:1 |
PTL: 59 (30-90) ATC: 67 (20-91) |
40 59 |
| Hahn et al. (2013) (45) | TL | Korea | 2006-2010 | N/A | N/A | 10 † |
| Kakkar et al. (2019) (25) | TL | India | 2009-2015 | 2.7:1 | 64,6 (40-76) | 11 |
| Jin et al. (2007) (54) | TL | Korea | 2003-2005 | 2:1 | 62,5 (56-72) | 6 |
| Nam et al. (2012) (47) | TL | Korea | 1995-2010 | 3.3:1 | 60,8 (43-82) | 13 |
| Pradhan et al. (2019) (48) | ATC | India | 1991-2013 | 1.2:1 | 58 (36-80) | 100 |
| Quesada et al. (2016) (11) | TL | USA | 2000-2015 | 0.8:1 | 41 (19-49) | 7 |
| Ruggiero et al. (2005) (49) | TL | USA | 1977-2004 | 2.7:1 | 76,5 | 22 |
| Sarinah et al. (2010) (50) | TL | Malaysia | 1998-2006 | 1.8:1 | 58 (31-82) | 17 |
| Sharma et al. (2016) (30) | TL | USA | 2000-2014 | 1:1 | 67 (N/A) | 75 |
| Stacchini et al. (2015) (46) | TL | Italy | 2001-2013 | 1.2:1 | 66 (33-89) | 13 |
| Suh et al. (2013) (23) | ATC | Korea | 2001-2011 | 2.6:1 | 70,5 (54-81) | 18 |
| Wu et al. (2016) (56) | TL | Taiwan | 1992-2015 | 1.5:1 | 67,9 (54-83) | 10 |
| Xu et al. (2021) (44) | TL and ATC | China | 2013-2018 | N/A (39-75) ‡ | 24 ‡ | |
| Yang et al. (2015) (53) | TL | China | 1995-2012 | 0.7:1 | 68,8 (N/A) | 12 |
| Total, n | 514 |
N/A, not available.
* Period of patient enrollment.
° Number of all patients included in the study. Not equal to number of patients who underwent CNB.
† refers only to patients included in the study with atc or ptl, excluding patients with diagnosis other than atc or ptl.
‡ Refers to entire study population, including patients with diagnosis other than ATC or PTL. Data on gender ratio was therefore not incorporated in Table 2 .